MAGNEVIST
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Jun 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAGNEVIST is an injectable small-molecule contrast agent approved by FDA in 1988 for diagnostic imaging across multiple vascular and oncologic indications. It is used to enhance visualization of renal artery stenosis, peripheral arterial disease, myocardial infarction, brain tumors, and breast cancer via magnetic resonance imaging (MRI). The drug functions as a gadolinium-based contrast medium that improves tissue differentiation in diagnostic imaging.
LOE Approaching
As LOE approaches, MAGNEVIST brand teams are likely contracting; careers here focus on lifecycle extension, generic defense, or transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (11)
Gadobutrol Magnevist-controlled Body Study
Started Jan 2010
370 enrolled
Magnetic Resonance Imaging
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Started Nov 2008
168 enrolled
FibrosisKidney FailureRenal Insufficiency
Magnevist Post-marketing Surveillance in Japan
Started Aug 2007
2,051 enrolled
Diagnostic Imaging
Multihance Versus Magnevist in Breast MRI
Started Jul 2007
130 enrolled
Breast Cancer
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography
Started Jul 2004
12 enrolled
Magnetic Resonance AngiographyPeripheral Vascular DiseasesPeripheral Arterial Diseases
Worked on MAGNEVIST at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.